Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tirapazamine: laboratory data relevant to clinical activity

J M Brown1, L H Wang

  • 1Department of Radiation Oncology, Stanford University School of Medicine, CA 94305, USA.

Anti-Cancer Drug Design
|October 2, 1998
PubMed
Summary

Tirapazamine (TPZ) is a bioreductive anticancer agent selectively toxic to hypoxic cells. Preclinical data suggest TPZ is likely clinically active, especially when combined with cisplatin.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A comparison of critical thinking abilities between accelerated and traditional baccalaureate nursing students.

The Journal of nursing education·1997
Same author

Samuel Eugene Harmon (1871-1935).

Journal of the South Carolina Medical Association (1975)·1997
Same author

Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine.

Cancer chemotherapy and pharmacology·1997
Same author

Three-dimensional structures of gonadotropins.

Molecular and cellular endocrinology·1996
Same author

Evaluation of monoclonal antibodies for generic detection of flaviviruses by ELISA.

Journal of virological methods·1996
Same author

The DNA damage response in DNA-dependent protein kinase-deficient SCID mouse cells: replication protein A hyperphosphorylation and p53 induction.

Proceedings of the National Academy of Sciences of the United States of America·1996

Area of Science:

  • Oncology
  • Pharmacology
  • Radiotherapy

Background:

  • Tirapazamine (TPZ) is a benzotriazine di-N-oxide bioreductive anticancer agent.
  • Its selective toxicity to hypoxic cells stems from DNA damage induced by a free radical species.
  • TPZ shows synergistic activity with fractionated irradiation and chemotherapy agents like cisplatin.

Purpose of the Study:

  • To review the clinical relevance of TPZ, focusing on its mechanism of action.
  • To elucidate the synergistic interaction between TPZ and cisplatin in hypoxic conditions.
  • To assess the cumulative toxicity and therapeutic dosage of TPZ for clinical application.

Main Methods:

  • Review of preclinical data on TPZ's mechanism of action and efficacy.
  • Analysis of synergistic effects of TPZ with cisplatin in experimental tumors.
  • Evaluation of TPZ's toxicity profile compared to other hypoxia-activated agents.
  • Pharmacokinetic analysis (area under the curve) in mice and humans to determine effective doses.

Main Results:

  • TPZ's mechanism involves one-electron reduction to a radical that causes DNA strand breaks and chromosomal aberrations.
  • Synergy between TPZ and cisplatin is significantly enhanced in hypoxic environments due to cellular interactions.
  • TPZ does not exhibit cumulative toxicity, unlike nitroimidazoles.
  • Calculated doses for Phase II and III trials are predicted to be clinically effective.

Conclusions:

  • Preclinical evidence strongly supports the clinical efficacy of Tirapazamine (TPZ).
  • TPZ is particularly promising when used in combination with cisplatin, especially in hypoxic tumors.
  • The lack of cumulative toxicity and adequate predicted dosing further support its clinical potential.

Related Experiment Videos